Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01850875
Other study ID # 01EC1010A
Secondary ID
Status Completed
Phase N/A
First received April 23, 2013
Last updated May 13, 2016
Start date May 2013
Est. completion date December 2015

Study information

Verified date May 2016
Source University Hospital Heidelberg
Contact n/a
Is FDA regulated No
Health authority Germany: Federal Ministry of Education and Research
Study type Interventional

Clinical Trial Summary

The study explores the feasibility of Eye-Movement-Desensitization and Reprocessing (EMDR) in non-specific chronic back pain.


Description:

The study explores the feasibility of Eye-Movement-Desensitization and Reprocessing (EMDR) in non-specific chronic back pain in a randomized controlled trial (RCT) with 6 months follow-up. The treatment consists of 12-sessions EMDR a 60 minutes using eye-movements for bilateral stimulation in addition to treatment as usual (TAU) that is compared to TAU alone.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date December 2015
Est. primary completion date November 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- >= 18 years

- non-specific chronic low back pain >= 45 days/3 months

- high emotional distress caused by psychological trauma

- German language skills

Exclusion Criteria:

- specific causes of chronic back pain

- application for retirement pension pending

- ongoing psychotherapy

- severe physical or psychiatric comorbidity

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Behavioral:
Eye-Movement-Desensitization-Reprocessing


Locations

Country Name City State
Germany University Hospital Heidelberg Heidelberg Baden-Württemberg

Sponsors (1)

Lead Sponsor Collaborator
University Hospital Heidelberg

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Other functional and structural changes in fMRI Change from Baseline fMRI at average 6 months No
Other Change in the pain experience scale - Pain affect Geisser et al., 1996 Change from Baseline pain experience scale levels at average 6 months No
Other Change in the Hannover functional ability questionnaire (FFbH) - disability Kohlmann et al., 1996 Change from Baseline disabilty levels at average 6 months No
Other Change in Quantitative sensory testing (QST)profiles According to the protocol by Rolke et al. (2006), developed within the Germany Research Network on Neuropathic Pain (DFNS) Change from Baseline QST profile at average 6 months No
Other Change in Conditioned Pain Modulation difference in pressure pain threshold before and after oscillating heat (2 min.) Change from Baseline conditioned pain modulation activity at average 6 months No
Other Change in Plasma endocannabinoids and lipids Plasma levels: AEA (ng/ml), 2-AG (ng/ml), AA (ng/ml), PEA (ng/ml), OEA (ng/ml), AEA (pmol/g), 2-AG (pmol/g), AA (nmol/g), PEA (pmol/g), OEA (pmol/g), Change from Baseline endocannabinoids and lipids at average 6 months No
Other Change in plasma nerve growth factor levels Plasma levels in (pg/ml) Change from Baseline NGF levels at average 6 months No
Other Change in pain drawing/ the spatial extent of the pain Change from Baseline Pain extent at average 6 months No
Other Change in West Haven-Yale multidimensional pain inventory scores Flor et al., 1990 Change from Baseline West Haven-Yale multidimensional pain inventory scores at average 6 months No
Other Change in chronic pain grade von Korff er al., 1992 Change from Baseline chronic pain grade at average 6 months No
Other Change in Resilience Scale (RS-11) scores Schumacher et al., 2004 Change from Baseline resilience scores at average 6 months No
Other Change in Hospital Anxiety and Depression Scale scores Zigmond & Snaith, 1983 Change from Baseline anxiety and depression levels at average 6 months No
Other Change in Health Survey scores SF-12 Change from baseline quality of life level at average 6 months No
Other Change in somatization scores SCL-90R Change from Baseline somatization scores at average 6 months No
Other Change in medication intake Change from Baseline medication intake at average 6 months No
Other Change in dissociation scores DES/FDS-20 Change from Baseline dissociation at average 6 months No
Other Change in Post Traumatic Diagnostic Scale Change from Baseline post traumatic diagnostic scale levels at average 6 months No
Other Patient global impression of change after on average 6 months of treatment No
Other Recruitment potential % of patients eligible for inclusion that give written informed consent 6 months No
Other Retention rate % of patients that finish treatment, including pre- and post-evaluation over average 6 months of treatment No
Primary Change in pain intensity Numerical rating scale 0-10 Change from Baseline Pain intensity at average 6 months No

External Links